Literature DB >> 15937215

Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.

Xi-Ping Huang1, Stefanie Prilla, Klaus Mohr, John Ellis.   

Abstract

The structurally divergent agents gallamine and hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide (W84) are known to interact competitively at a common allosteric site on muscarinic receptors. Previous studies reported that the M2 selectivity of gallamine depended largely on the EDGE (172-175) sequence in the second outer loop (o2) and on 419Asn near the junction of o3 and the seventh transmembrane domain (TM7), whereas the selectivity of W84 depended on nearby residues 177Tyr and 423Thr. However, it has so far proven difficult to confer the high sensitivity for allosteric modulation of the M2 subtype onto the weakly sensitive M5 subtype by substituting these key residues. We now have found that M2 423Thr, not 419Asn, is the dominant residue in the o3/TM7 region for gallamine's high potency, although 419Asn can substitute for 423Thr in some contexts; in contrast, the presence of 419Asn reduces the potency of W84 in every context we have studied. In addition, the orientation of 177Tyr is crucial to high sensitivity toward W84, and it seems that the proline residue at position 179 in M5 (corresponding to M2 172Glu) may interfere with that orientation. Consistent with these observations, a mutant M5 receptor with these three key mutations, M5P179E, Q184Y, and H478T, showed dramatically increased sensitivity for W84 (>100-fold), compared with the wild-type M5 receptor. This same mutant receptor approached M2 sensitivity toward gallamine. Thus, gallamine and W84 derive high potency from the same receptor domains (epitopes in o2 and near the junction between o3 and TM7), even though these allosteric agents have quite different structures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937215     DOI: 10.1124/mol.105.014043

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

1.  Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.

Authors:  Vindhya Nawaratne; Katie Leach; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-04-20       Impact factor: 5.157

2.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

3.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Authors:  Ron O Dror; Hillary F Green; Celine Valant; David W Borhani; James R Valcourt; Albert C Pan; Daniel H Arlow; Meritxell Canals; J Robert Lane; Raphaël Rahmani; Jonathan B Baell; Patrick M Sexton; Arthur Christopoulos; David E Shaw
Journal:  Nature       Date:  2013-10-13       Impact factor: 49.962

4.  Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.

Authors:  Maren Grossmüller; Johannes Antony; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

5.  A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation.

Authors:  Monika Maier-Peuschel; Nadine Frölich; Christian Dees; Leif G Hommers; Carsten Hoffmann; Viacheslav O Nikolaev; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

6.  Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Authors:  Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

Review 7.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

8.  Novel allosteric effects of amiodarone at the muscarinic M5 receptor.

Authors:  Edward Stahl; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-26       Impact factor: 4.030

9.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Authors:  W Y Chan; D L McKinzie; S Bose; S N Mitchell; J M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; F P Bymaster; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

10.  Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Authors:  Katie Leach; Richard E Loiacono; Christian C Felder; David L McKinzie; Adrian Mogg; David B Shaw; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropsychopharmacology       Date:  2009-11-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.